Skin & Soft Tissue Diseases

Freeze-drying vaccines enables health officials to get vaccines to remote areas, but until now, it has not been possible for the fragile polio vaccine.

The new test is approved to assist with detecting cytomegalovirus in newborns less than 21 days of age.

Polio could soon be completely eradicated, but public health officials have an intricate set of steps to ensure a lasting defeat.

New outbreaks of rubella and troubling data on influenza highlight the importance of vaccination.

Herpes simplex virus type 1 is associated with a higher risk of Alzheimer’s disease, yet the antivirals prescribed to treat the infection may reduce the risk of dementia.

A recent report has described a case of wound infection with the bacterium Burkholderia thailandensis in a woman in Arkansas.

The stage may finally be set for the phage therapy era for recalcitrant bacterial infections.

Results indicate patients who received single-dose oritavancin were significantly less likely to be hospitalized, compared to those who received multidose vancomycin.

Instead, increasing duration of postoperative antimicrobial prophylaxis is associated with higher odds of acute kidney injury and C diff infection in a dose-dependent manner.

Delafloxacin was found to be relatively safe and well tolerated in patients with acute bacterial skin and skin structure infections with past or present cardiac or vascular difficulties.

Nonadherence to antiretroviral therapy was associated with a higher risk of death.

Plenty of research has gone into the causes and progression of Alzheimer’s disease. Now a new effort aims to make the case that scientists have been looking in the wrong direction.

Patients with diabetes who were treated for acute bacterial skin and skin structure infections (ABSSSIs) with iclaprim had fewer adverse events (AEs) than those who were treated with vancomycin, according to the results of a recent study.

Common skin bacteria have gained resistance to multiple antibiotics.

Rezafungin, an investigational antifungal, demonstrated significant activity against Aspergillus in an in vitro study.

A social media campaign initiated in Russia may be sowing the seeds of debate surrounding vaccine safety, causing new outbreaks of measles globally.

Additional evidence supports the use of oritavancin as a cost-saving outpatient treatment for acute bacterial skin and skin structure infections (ABSSTIs) in patients who would otherwise be admitted to the hospital for therapy.

In a wounded mouse model concurrently infected with influenza A, investigators observed that the innate immune system prioritized responding to the lung infection, delaying wound healing.

There is a new treatment for this old disease, so why are we still worried?

New geographical spread of the disease may warrant increased vigilance among labs and clinicians.

The PDUFA action date has been set for February 13, 2019.

The FDA advisory committee voted 17 to 1 in favor of omadacycline for treatment of ABSSSI and 14 to 4 for the treatment of CABP.

Following cases of vibriosis in New Jersey, Alabama, and Florida, health officials are telling individuals with open wounds to stay out of coastal or brackish waters.

Development of the drug has been deemed necessary because of the potential for the use of the virus in a bioterrorism attack and waning herd immunity against the virus among the general population.

Preliminary studies provide convincing evidence for the synergistic use of sulfonamide agents with azole antifungals.

Research presented at the 2018 ASM Microbe Meeting has reinforced the value of the just-approved next-generation aminoglycoside antibiotic, plazomicin, in treating multidrug-resistant Enterobacteriaceae.

Because of the global rise in antimicrobial resistance, meropenem-vaborbactam, the first carbapenem/β-lactamase combina­tion medication, is a welcome new antibac­terial.

Skin and soft tissue infections appear to be on the decline in the general population, but individuals with HIV have a higher risk.

Several recent studies provide valuable insight surrounding the appropriateness of transitioning from intravenous to oral therapy when treating bacteremic urinary tract infections.